MG132-mediated inhibition of the ubiquitin–proteasome pathway ameliorates cancer cachexia (original) (raw)

• Adams V et al (2008) Induction of MuRF1 is essential for TNF-alpha-induced loss of muscle function in mice. J Mol Biol 384(1):48–59
  Article PubMed CAS Google Scholar
• Agustsson T et al (2007) Mechanism of increased lipolysis in cancer cachexia. Cancer Res 67(11):5531–5537
  Article PubMed CAS Google Scholar
• Ahmed AS et al (2010) Attenuation of pain and inflammation in adjuvant-induced arthritis by the proteasome inhibitor MG132. Arthritis Rheum 62(7):2160–2169
  PubMed CAS Google Scholar
• Argiles JM, Lopez-Soriano FJ (1999) The role of cytokines in cancer cachexia. Med Res Rev 19(3):223–248
  Article PubMed CAS Google Scholar
• Bodine SC et al (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294(5547):1704–1708
  Article PubMed CAS Google Scholar
• Cai D et al (2004) IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119(2):285–298
  Article PubMed CAS Google Scholar
• Cao PR, Kim HJ, Lecker SH (2005) Ubiquitin-protein ligases in muscle wasting. Int J Biochem Cell Biol 37(10):2088–2097
  Article PubMed CAS Google Scholar
• Caron AZ et al (2011) The proteasome inhibitor MG132 reduces immobilization-induced skeletal muscle atrophy in mice. BMC musculoskeletal disord 12:185
  Article CAS Google Scholar
• Carson JA, Baltgalvis KA (2010) Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev 38(4):168–176
  Article PubMed Google Scholar
• Dodson S et al (2011) Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 62:265–279
  Article PubMed CAS Google Scholar
• Faber J et al (2008) Beneficial immune modulatory effects of a specific nutritional combination in a murine model for cancer cachexia. Br J Cancer 99(12):2029–2036
  Article PubMed CAS Google Scholar
• Fearon KC (2008) Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 44(8):1124–1132
  Article PubMed CAS Google Scholar
• Fearon K et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489–495
  Article PubMed Google Scholar
• Glass DJ (2010) Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr Metab Care 13(3):225–229
  Article PubMed CAS Google Scholar
• Gomes MD et al (2001) Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 98(25):14440–14445
  Article PubMed CAS Google Scholar
• Guo N, Z. Peng (2012) MG132 a proteasome inhibitor, induces apoptosis in tumor cells. Asia-Pacific j clin oncol
• Guttridge DC et al (2000) NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289(5488):2363–2366
  Article PubMed CAS Google Scholar
• Holroyde CP et al (1984) Glucose metabolism in cachectic patients with colorectal cancer. Cancer Res 44(12 Pt 1):5910–5913
  PubMed CAS Google Scholar
• Inoue S et al (2009) The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease. Clin Exp Immunol 156(1):172–182
  Article PubMed CAS Google Scholar
• Jamart C et al (2011) Prevention of muscle disuse atrophy by MG132 proteasome inhibitor. Muscle Nerve 43(5):708–716
  Article PubMed CAS Google Scholar
• Jing H et al (2012) MG132 alleviates liver injury induced by intestinal ischemia/reperfusion in rats: involvement of the AhR and NFkappaB pathways. J surg res 176(1):63–73
  Article PubMed CAS Google Scholar
• Judge AR et al (2007) Role for IkappaBalpha, but not c-Rel, in skeletal muscle atrophy. Am J Physiol Cell Physiol 292(1):C372–C382
  Article PubMed CAS Google Scholar
• Kawamura I et al (1999) Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. Gene Ther 6(1):91–97
  Article PubMed CAS Google Scholar
• Kumar A et al (2004) Nuclear factor-kappaB: its role in health and disease. J Mol Med 82(7):434–448
  Article PubMed CAS Google Scholar
• Li H, Malhotra S, Kumar A (2008) Nuclear factor-kappa B signaling in skeletal muscle atrophy. J Mol Med 86(10):1113–1126
  Article PubMed CAS Google Scholar
• Lombardo T et al (2012) Synergism between arsenite and proteasome inhibitor MG132 over cell death in myeloid leukemic cells U937 and the induction of low levels of intracellular superoxide anion. Toxicol Appl Pharmacol 258(3):351–366
  Article PubMed CAS Google Scholar
• Ma Y et al (2011) MG132 treatment attenuates cardiac remodeling and dysfunction following aortic banding in rats via the NF-kappaB/TGFbeta1 pathway. Biochem Pharmacol 81(10):1228–1236
  Article PubMed CAS Google Scholar
• Melstrom LG et al (2007) Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia. Histol Histopathol 22(7):805–814
  PubMed CAS Google Scholar
• O’Leary EM, Igdoura SA (2012) The therapeutic potential of pharmacological chaperones and proteosomal inhibitors, Celastrol and MG132 in the treatment of sialidosis. Mol Genet Metab 107(1–2):173–185
  Article PubMed Google Scholar
• Pajak B et al (2008) Crossroads of cytokine signaling–the chase to stop muscle cachexia: an official. J physiol pharmacol 59(Suppl 9):251–264
  PubMed Google Scholar
• Saini A, Al-Shanti N, Stewart CE (2006) Waste management—cytokines, growth factors and cachexia. Cytokine Growth Factor Rev 17(6):475–486
  Article PubMed CAS Google Scholar
• Schneider M et al (2012) Severe acute respiratory syndrome coronavirus replication is severely impaired by MG132 due to proteasome-independent inhibition of M-calpain. J Virol 86(18):10112–10122
  Article PubMed CAS Google Scholar
• Sung ES et al (2012) The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells. Exp Cell Res 318(13):1564–1576
  Article PubMed CAS Google Scholar
• Tanaka Y et al (1990) Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res 50(8):2290–2295
  PubMed CAS Google Scholar
• Thaloor D et al (1999) Systemic administration of the NF-kappaB inhibitor curcumin stimulates muscle regeneration after traumatic injury. American j physiol 277(2 Pt 1):C320–C329
  CAS Google Scholar
• Tisdale MJ (2009) Mechanisms of cancer cachexia. Physiol Rev 89(2):381–410
  Article PubMed CAS Google Scholar
• Wang H et al (2011a) Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia. Cancer Lett 305(1):40–49
  Article PubMed CAS Google Scholar
• Wang Y et al (2011b) Comparative study of the influence of proteasome inhibitor MG132 and ganciclovir on the cytomegalovirus-specific CD8(+) T-cell immune response. Viral Immunol 24(6):455–461
  Article PubMed Google Scholar
• Winder SJ et al. (2011) The proteasomal inhibitor MG132 prevents muscular dystrophy in zebrafish. PLoS currents, 3: p. RRN1286
• Zanotto-Filho A et al (2012) Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3 K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK 1/2 signaling. Invest New Drugs 30(6):2252–2262
  Article PubMed CAS Google Scholar
• Zhou X et al (2010) Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142(4):531–543
  Article PubMed CAS Google Scholar